Treatment
Consolidation Therapy clinical trials
We’re tracking 63 recruiting studies that include Consolidation Therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT07415005RecruitingPhase 2
Lorlatinib and local therapy for ALK-positive lung cancer
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Houston, TexasAges 18 years+ - NCT07309211Recruiting
Durvalumab as maintenance therapy for limited-stage small cell lung cancer
This trial is for people with limited-stage small cell lung cancer who have already finished chemotherapy and radiation, and then started taking Durvalumab (Imfinzi) as a maintenance therapy. The goal is to see if continuing Durvalumab helps keep the cancer from coming back.
JinanAges 18 years+ - NCT06095583RecruitingPhase 3
Toripalimab for limited-stage small cell lung cancer after chemoradiation
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
Harbin, HeilongjiangAges 18 years+ - NCT05623267RecruitingPhase 2/Phase 3
SugeMalimab after lung radiation and chemotherapy for limited-stage SCLC
This trial tests sugemalimab as “extra treatment” after standard chemoradiation for limited-stage small cell lung cancer. It aims to lower the chance of the cancer coming back by helping the immune system stay active after initial therapy.
Guangzhou, GuangdongAges 18 years+ - NCT06232694Recruiting
Combination therapy for newly diagnosed AML
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Nanjing, JiangsuAges 18–60 - NCT06507514RecruitingPhase 1
Blinatumomab with stem cell transplant for B-ALL
This trial tests a treatment plan that uses blinatumomab (a drug that helps your immune system attack leukemia cells) combined with your own stem cell transplant. It is for people with B-ALL who cannot or choose not to have a transplant from another person.
Suzhou, JiangsuAges 15–65 - NCT06719700RecruitingPhase 2
Chemo-radiation with two drugs for limited-stage small cell lung cancer
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18–75 - NCT06990321RecruitingPhase 3
Cytarabine and venetoclax for older adults with AML
This trial tests a combination of two chemotherapy drugs, medium-dose cytarabine and venetoclax, as a follow-up treatment (consolidation) to keep leukemia from coming back. It is for older adults with intermediate or high-risk acute myeloid leukemia who have already achieved remission after their first round of therapy.
Changchun, JilinAges 60–75 - NCT07072494RecruitingPhase 1/Phase 2
CD19 CAR-T cells as consolidation for B-cell ALL
This trial tests a single infusion of CD19 CAR-T cells as a consolidation treatment to keep leukemia in remission for patients who are not eligible for or decline a stem cell transplant. The goal is to see if this therapy can prevent relapse.
Guangzhou, GuangdongAges 14–80 - NCT07086456RecruitingPhase 2
Combination therapy for advanced lung cancer
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07108998RecruitingPhase 2
Epcoritamab as a follow-up treatment for CLL or SLL
This trial tests the drug epcoritamab as a consolidation therapy for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have had a partial response to a second-generation BTK inhibitor (with or without obinutuzumab) but still have detectable disease. The goal is to see if adding this treatment can lead to a deeper response and better outcomes.
Cincinnati, OhioAges 18 years+ - NCT02605421RecruitingPhase 2
High-risk neuroblastoma stem cell treatment after initial response
This Phase 2 study tests intensive treatment (high-dose “consolidation”) followed by rescue with your own stem cells for high-risk neuroblastoma. It may help patients keep the cancer from coming back after it has improved or stabilized from initial chemotherapy.
Minneapolis, MinnesotaAges Up to 30 years - NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
AdelaideAges 18–18 - NCT06758830RecruitingPhase 2/Phase 3
Total neoadjuvant therapy vs surgery for rectal cancer
This trial tests whether a full course of chemotherapy and radiation before any surgery (called total neoadjuvant therapy) can help you avoid surgery and preserve your rectum. It is for people with a specific early stage of rectal cancer that has not spread.
VilniusAges 18 years+ - NCT05724004Recruiting
Alectinib then targeted radiation for ALK-positive lung cancer
This trial tests giving alectinib first, then adding targeted radiation to remaining spots of cancer in people with ALK-rearranged advanced non-small cell lung cancer. It aims to control the cancer after an initial response and help keep disease from progressing.
StockholmAges 20 years+ - NCT07048457RecruitingPhase 2
Surgery for metastatic bladder cancer after initial treatment
This trial tests whether removing the primary bladder tumor and any remaining metastatic spots after initial medication (enfortumab-vedotin) improves outcomes for people with a limited number of metastases (5 or fewer). It is for those whose cancer has responded or stabilized on treatment.
New Haven, ConnecticutAges 18 years+ - NCT07489534RecruitingPhase 2
CAR-T therapy for multiple myeloma with kidney problems
This trial tests a new type of cell therapy (CAR-T cells) for people with multiple myeloma who also have kidney problems. It aims to see if this treatment can help keep the cancer in remission after initial therapy.
Beijing, Beijing MunicipalityAges 14 years+ - NCT07575919RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Standard-Risk B-ALL After Chemotherapy
This trial tests a new type of immunotherapy called CAR-T cells to help prevent relapse in adults with B-cell acute lymphoblastic leukemia (a blood cancer) who have responded well to standard chemotherapy. The treatment is designed as a consolidation therapy to strengthen remission after initial chemotherapy.
Beijing, Beijing MunicipalityAges 18–85 - NCT07575971RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for High-Risk B-Cell Acute Lymphoblastic Leukemia
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target leukemia cells after chemotherapy has put your disease into remission. The goal is to help prevent the leukemia from coming back, especially for patients at high risk of relapse.
Beijing, Beijing MunicipalityAges 18–85 - NCT07161388Recruiting
Durvalumab after chemoradiation for limited-stage small cell lung cancer
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
BeijingAges 18 years+ - NCT07052669RecruitingPhase 3
Shorter Chemo-Radiation Plus Immunotherapy for Stage III Lung Cancer
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT03046316Recruiting
Local treatment for advanced lung cancer that hasn’t worsened
This trial looks at whether using focused treatments (like surgery or radiation to lung cancer spots) can help people with advanced non-small cell lung cancer whose disease has not progressed after first-line treatment. It’s meant for people who have limited metastatic spots and can safely undergo the local treatment.
Guangzhou, GuagndongAges 18 years+ - NCT05366829RecruitingPhase 2
Tislelizumab after liver tumor radiation to reduce cancer return
This Phase 2 trial tests tislelizumab (an immunotherapy medicine) given after liver-directed radiation to help prevent hepatocellular carcinoma (liver cancer) from coming back or spreading. It may help by boosting the immune system to better control remaining cancer.
New Brunswick, New JerseyAges 18 years+ - NCT06287398RecruitingPhase 2
Epcoritamab and chemo before stem cell transplant for relapsed large B-cell lymphoma
This trial tests a combination of a new immunotherapy drug called epcoritamab with chemotherapy, followed by a stem cell transplant and more epcoritamab, for people whose large B-cell lymphoma has returned after initial treatment. The goal is to see if this approach can help more people achieve remission and stay in remission.
Melbourne, VictoriaAges 18 years+
Common questions
- Are there clinical trials studying Consolidation Therapy?
- Yes. Clin2 currently lists 63 recruiting studies that include Consolidation Therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Consolidation Therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Consolidation Therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Consolidation Therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.